Care Rail

← Medical · All 20 for Interstitial lung disease

Taiwan

Interstitial lung disease · Respiratory

High ambulatory volume; global budgets constrain growth. Respiratory pathway via NHI single payer.

Rank in this country#34
Share of deaths0.7%
Master rank#34
System quality rank#12

Access & coverage

NHI single payer

NHI single payer with smart-card claims; low waiting

Treatment

  • Inhaled bronchodilators / steroids per phenotype
  • Oxygen / NIV for advanced disease
  • Exacerbation pathways and hospital-at-home where available

Prevention

  • Tobacco control; clean air / occupational dust rules
  • Vaccination (flu, pneumococcal, COVID) for high-risk groups
  • Early COPD case-finding in smokers

Lifestyle

  • Smoking cessation is the dominant lever
  • Pulmonary rehab exercise + breathing training
  • Avoid indoor smoke and occupational triggers

What stands out here

Same broad respiratory toolkit as peers — differences are coverage rules, wait times, prices, and follow-through.

vs master: -0.0 percentage points vs Top 20 average share.